C. Paul
Centre National de la Recherche Scientifique(FR)Université Toulouse III - Paul Sabatier(FR)Inserm(FR)Inserm(FR)Christian Medical College, Vellore(IN)Christian Medical College & Hospital(IN)Université de Toulouse(FR)Université Fédérale de Toulouse Midi-Pyrénées(FR)Centre Hospitalier Universitaire de Toulouse(FR)Centre de Recherche en Cancérologie de Toulouse(FR)Centre Hospitalier de Niort(FR)Christian Medical College(IN)Hôpital Larrey(FR)Centre d'Immunologie et des Maladies Infectieuses(FR)Institut des Maladies Métaboliques et Cardiovasculaires(FR)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Allergic Rhinitis and Sensitization, Urticaria and Related Conditions
Most-Cited Works
- → Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials(2015)818 cited
- → Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis(2015)792 cited
- → First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial(2017)587 cited
- → Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey(2014)507 cited
- → Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)(2015)472 cited
- → A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis